• By ICR Secretariat
  • Posted Wednesday, June 15, 2022

Bristol Myers’ autoimmune drug shows potential in lupus

https://www.biopharmadive.com/news/bristol-myers-deucravacitinib-lupus-tky2-trial/624696/

  • Bristol Myers Squibb’s experimental autoimmune disease drug deucravacitinib helped treat moderate-to-severe lupus in a Phase 2 trial, the company reported Wednesday. Results, which were presented at a medical conference in Denmark, showed two doses of the pill led to significantly higher response rates than did a placebo.